7Baggers
 Exit strategy if you’re trapped in Salarius Pharmaceuticals Inc.  newser.com Fri, 03 Oct 2025 06:01:36 GMT
 Salarius Pharmaceuticals Stock Plummets to 52-Week Low of $4.23  Markets Mojo Sun, 21 Sep 2025 00:51:13 GMT
 published on: 2025-09-19 06:42:55  newser.com Fri, 19 Sep 2025 11:42:55 GMT
 published on: 2025-09-18 21:39:35  newser.com Fri, 19 Sep 2025 02:39:35 GMT
 published on: 2025-09-15 17:38:17  newser.com Mon, 15 Sep 2025 22:38:17 GMT
 published on: 2025-09-16 17:41:37  newser.com Sat, 13 Sep 2025 22:47:19 GMT
 published on: 2025-09-13 17:47:19  newser.com Sat, 13 Sep 2025 22:47:19 GMT
 salarius pharmaceuticals announces reverse stock split  MSN Fri, 12 Sep 2025 06:27:21 GMT
 Salarius Pharmaceuticals Regains Nasdaq Compliance  The Globe and Mail Wed, 10 Sep 2025 07:00:00 GMT
 Salarius Pharmaceuticals Regains Nasdaq Compliance  TipRanks Tue, 09 Sep 2025 07:00:00 GMT
 published on: 2025-09-04 23:04:02  Newser Fri, 05 Sep 2025 04:04:02 GMT
 published on: 2025-09-02 13:15:45  Newser Tue, 02 Sep 2025 18:15:45 GMT

Salarius Pharmaceuticals, Inc
(NASDAQ:SLRX) 

SLRX stock logo

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ...

Founded: 2014
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends